Screening & TReatment fOr Perinatal WomeN With PTSD in Substance Use Care SettinGs in Arkansas (STRONG Moms) (STRONG Moms)
調査の概要
詳細な説明
The primary objective is to evaluate the feasibility and acceptability of implementing a brief, telehealth-delivered behavioral intervention for PTSD among pregnant and postpartum individuals with a history of substance misuse. Secondary objectives include estimating the prevalence of probable PTSD in perinatal substance use treatment settings, assessing participant interest in receiving PTSD treatment while engaged in substance use care, and examining preliminary changes in PTSD and depressive symptoms following treatment.
The study consists of two sequential components. First, pregnant and postpartum individuals receiving services for problematic substance misuse in Arkansas will be screened for PTSD symptoms using the Primary Care PTSD Screen for DSM-5 (PC-PTSD-5). Screening will be conducted across multiple treatment and care settings, including inpatient and outpatient programs, to estimate the prevalence of probable PTSD and characterize willingness to participate in trauma-focused treatment during the perinatal period.
Second, individuals who meet eligibility criteria for PTSD treatment will participate in a mixed-methods, single-arm pre-post pilot evaluation of Written Exposure Therapy (WET), a brief evidence-based behavioral intervention for PTSD delivered via telehealth. Approximately 20 pregnant and postpartum participants with PTSD will receive the intervention. Feasibility will be assessed through measures such as recruitment, enrollment, retention, intervention completion, and assessment completion. Acceptability will be evaluated using participant-reported satisfaction and qualitative interviews exploring experiences with treatment delivery, barriers and facilitators to participation, and recommendations for implementation. Clinical assessments conducted before and after treatment will provide preliminary estimates of changes in PTSD symptoms and depressive symptoms.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Mollee K. Steely Smith K Assistant Professor, PhD
- 電話番号:501-526-8174
- メール:mksteelysmith@uams.edu
研究連絡先のバックアップ
- 名前:Chelsey E Bull, PhD
- メール:cebull@uams.edu
研究場所
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72205
- University of Arkansas for Medical Sciences
-
コンタクト:
- Mollee K Steely Smith, PhD
- 電話番号:501-526-8174
- メール:mksteelysmith@uams.edu
-
コンタクト:
- Chelsey E Bull, PhD
- メール:cebull@uams.edu
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Able to write, understand, and speak English
- Able to give informed consent
- Currently pregnant or postpartum (≤ 6 months after childbirth)
- History of substance misuse
- Receiving services for substance-use related problems
- Have a history of traumatic event exposure
- Endorse clinically significant PTSD symptoms (score ≥ 3 on the Primary Care PTSD Screen for DSM-5; PC-PTSD-5)
Exclusion Criteria:
- Unwilling to provide consent
- No history of Criterion A trauma exposure or clinically significant PTSD symptoms
- No history of substance misuse or currently receiving services for a substance-use related problem
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Single Arm Intervention
All participants will receive Written Exposure Therapy (WET)
|
Written Exposure Therapy (WET) is a brief, evidence-based therapy for PTSD.
Clients receive 5 weekly sessions where they write about a traumatic experience in a safe, structured way for approximately 50 minutes followed by a brief check-in with their therapist.
This process helps individuals make sense of the event, reduce emotional distress, and decrease PTSD symptoms over time.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Acceptability
時間枠:From baseline to end of treatment at 5 weeks
|
Acceptability will be evaluated using the Client Satisfaction Questionnaire (CSQ-8), an 8-item participant-reported satisfaction measure rated on a 4-point Likert scale.
Total scores ranging from 8-32, with higher scores indicating greater satisfaction with the therapy.
|
From baseline to end of treatment at 5 weeks
|
|
Acceptability
時間枠:From baseline to end of treatment at 5 weeks
|
Acceptability will also be evaluated using the Acceptability of Intervention (AIM), which is a 4-item self-reported questionnaire on a 5-point Likert scale assessing acceptability of the intervention.
Scores are summed and higher scores indicate greater acceptability.
|
From baseline to end of treatment at 5 weeks
|
|
Feasibility of Recruitment
時間枠:From enrollment to end of treatment at 5 weeks
|
Feasibility of recruitment will be assessed by the number of individuals who initiated WET versus the total number of individuals enrolled in the study.
|
From enrollment to end of treatment at 5 weeks
|
|
Therapy Adherence
時間枠:From enrollment to end of treatment at 5 weeks
|
Therapy adherence will be assessed by WET session attendance and completion.
We will measure therapy adherence by the number of individuals who complete ≥ 4 sessions versus the total number of individuals who received ≤ 3 sessions.
|
From enrollment to end of treatment at 5 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PTSD Symptoms
時間枠:From enrollment to the end of treatment at 5 weeks
|
Changes in PTSD symptoms will be assessed using the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report questionnaire on symptoms of PTSD.
Scores range from 0-80, with higher scores indicating a greater PTSD symptom severity.
|
From enrollment to the end of treatment at 5 weeks
|
|
Depression Symptoms
時間枠:From enrollment to end of treatment at 5 weeks
|
Depression symptoms will be assessed using the Personal History Questionnaire (PHQ-9), a 9-item questionnaire used to assess depression symptoms over the past 2 weeks.
Total scores range from 0-27, with higher scores indicating greater severity of depression symptoms
|
From enrollment to end of treatment at 5 weeks
|
|
Substance Use Severity
時間枠:From enrollment to end of treatment at 5 weeks
|
The DSM-5 Drug Use Disorder (DUD) and Alcohol Use Disorder (AUD) Symptom Checklist is a self-report measure to assess the presence of diagnostic criteria for drug use disorders.
This measure evaluates the 11 DSM-5 criteria for drug use disorders, including impaired control, social impairment, risky use, and pharmacologic indicators (tolerance/withdrawal).
Endorsement of a greater number of criteria indicates greater severity and can be categorized as mild, moderate, or severe.
|
From enrollment to end of treatment at 5 weeks
|
|
Pre/Postnatal Depression Symptoms
時間枠:From enrollment to the end of treatment at 5 weeks
|
The Edinburgh Postnatal Depression Scale (EPDS), a 10-item self-report questionnaire to assess depressive symptoms experiences during the previous 7 days in pregnant and postpartum individuals, will also be used to assess perinatal postpartum depression.
Total scores range from 0-30, with higher scores indicating greater severity of depressive symptoms.
|
From enrollment to the end of treatment at 5 weeks
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Mollee K Steely Smith, PhD、University of Arkansas
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 300210
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。